Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry - PubMed (original) (raw)
Multicenter Study
. 2009 Nov;45(16):2835-42.
doi: 10.1016/j.ejca.2009.06.010. Epub 2009 Jul 16.
Stefano Parodi, Bruno De Bernardi, Daniela Dau, Carla Manzitti, Massimo Conte, Fiorina Casale, Elisabetta Viscardi, Maurizio Bianchi, Paolo D'Angelo, Giulio Andrea Zanazzo, Roberto Luksch, Claudio Favre, Angela Tamburini, Riccardo Haupt
Affiliations
- PMID: 19616426
- DOI: 10.1016/j.ejca.2009.06.010
Multicenter Study
Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry
Alberto Garaventa et al. Eur J Cancer. 2009 Nov.
Abstract
The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relapse (P<0.001). Probability of survival increased by era of diagnosis. Survival of children with recurrent neuroblastoma is very poor. A small cohort of patients, mainly represented by children with stages 1 and 2 who underwent local recurrence or developed late relapse may still benefit from further conventional treatment. For the remaining larger proportion of patients, experimental therapies should be proposed.
Similar articles
- Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.
Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, Luksch R, Di Cataldo A, Favre C, D'Angelo P, Zanazzo GA, Arcamone G, Izzi GC, Gigliotti AR, Pastore G, De Bernardi B. Haupt R, et al. J Clin Oncol. 2010 May 10;28(14):2331-8. doi: 10.1200/JCO.2009.24.8351. Epub 2010 Mar 29. J Clin Oncol. 2010. PMID: 20351331 - Neuroblastoma in adolescents: the Italian experience.
Conte M, Parodi S, De Bernardi B, Milanaccio C, Mazzocco K, Angelini P, Viscardi E, Di Cataldo A, Luksch R, Haupt R. Conte M, et al. Cancer. 2006 Mar 15;106(6):1409-17. doi: 10.1002/cncr.21751. Cancer. 2006. PMID: 16475209 - Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry.
Ceschel S, Casotto V, Valsecchi MG, Tamaro P, Jankovic M, Hanau G, Fossati F, Pillon M, Rondelli R, Sandri A, Silvestri D, Haupt R, Cuttini M. Ceschel S, et al. Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6. doi: 10.1002/pbc.20726. Pediatr Blood Cancer. 2006. PMID: 16395684 - Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR. London WB, et al. Cancer. 2017 Dec 15;123(24):4914-4923. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. Cancer. 2017. PMID: 28885700 Free PMC article. Review. - Neuroblastoma Interaction with the Tumour Microenvironment and Its Implications for Treatment and Disease Progression.
Jahangiri L. Jahangiri L. Curr Oncol. 2023 Oct 15;30(10):9116-9140. doi: 10.3390/curroncol30100659. Curr Oncol. 2023. PMID: 37887559 Free PMC article. Review.
Cited by
- Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.
Mao C, Poimenidou M, Craig BT. Mao C, et al. Cancers (Basel). 2024 Aug 17;16(16):2865. doi: 10.3390/cancers16162865. Cancers (Basel). 2024. PMID: 39199637 Free PMC article. Review. - Narrative review: precision medicine applications in neuroblastoma-current status and future prospects.
Zhou J, Du H, Cai W. Zhou J, et al. Transl Pediatr. 2024 Jan 29;13(1):164-177. doi: 10.21037/tp-23-557. Epub 2024 Jan 24. Transl Pediatr. 2024. PMID: 38323175 Free PMC article. Review. - Three-dimensional in vitro model of bone metastases of neuroblastoma as a tool for pharmacological evaluations.
Aveic S, Seidelmann M, Davtalab R, Corallo D, Vogt M, Rütten S, Fischer H. Aveic S, et al. Nanotheranostics. 2024 Jan 1;8(1):1-11. doi: 10.7150/ntno.85439. eCollection 2024. Nanotheranostics. 2024. PMID: 38164505 Free PMC article. - Clinical value of combined serum CA125, NSE and 24-hour urine VMA for the prediction of recurrence in children with neuroblastoma.
Li J, Qi Z, Chen M, Wang J, Liu X. Li J, et al. Ital J Pediatr. 2023 Aug 24;49(1):102. doi: 10.1186/s13052-023-01508-6. Ital J Pediatr. 2023. PMID: 37620978 Free PMC article. - A novel nomogram for predicting post-recurrence survival in recurrent neuroblastoma patients.
Chen WM, Fang YY, Lin P, Bai JX, Fang YF, Zhang B. Chen WM, et al. Am J Cancer Res. 2023 Jun 15;13(6):2254-2268. eCollection 2023. Am J Cancer Res. 2023. PMID: 37424797 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical